Centrus Energy (LEU) experienced a modest decline in its stock price on Wednesday, falling 0.8% to $184.02 by 1:00 p.m. ET, even after announcing a definitive multiyear agreement to supply high-assay low-enriched uranium (HALEU) to Radiant Industries. The muted market reaction was not entirely unexpected, given that the contract, while strategically significant, did not disclose key financial figures such as the total contract value or the volume of fuel to be delivered.
The agreement with Radiant, a privately-held developer of microreactors, marks a notable validation of Centrus's HALEU production capabilities. HALEU is a specialized fuel necessary for many advanced reactor designs, and Centrus is currently the only U.S.-based commercial producer. The contract includes prepayments from Radiant, which will help fund Centrus's ongoing expansion of its enrichment capacity at its Piketon, Ohio facility. These prepayments are a crucial element, as they shift some of the financial burden from Centrus's shareholders to a future customer, providing more tangible evidence of demand than a non-binding memorandum of understanding.
The strategic importance of the fuel is underscored by its U.S.-origin status. Centrus's AC100 centrifuge technology and domestic manufacturing chain ensure that the HALEU produced is 'unobligated,' meaning it can be used for both commercial and national security applications. This is particularly relevant for Radiant, whose Kaleidos microreactor is being developed for defense installations and remote power needs.
Why the Market Remains Cautious
Despite the positive news, investors were not rushing to bid up the stock. The announcement lacks four critical data points needed to model cash flow: the contract's dollar value, the quantity of HALEU in kilograms, the delivery timeline, and the size of the prepayments. While mentioning 'multiple' reactors establishes a customer relationship, it does not clarify whether Radiant will become a material contributor to Centrus's revenue relative to its existing backlog.
Centrus already has a substantial backlog, totaling $4.5 billion as of June 30, with $3.7 billion attributed to its low-enriched uranium (LEU) segment. However, a significant portion of these commitments—approximately $3.0 billion—are contingent, with $2.4 billion under definitive agreements. These contingencies are often tied to operational milestones, such as the successful completion of Centrus's commercial enrichment facility. This distinction is key: a signed fuel contract can strengthen the case for building capacity without producing near-term revenue. For instance, Centrus's average fulfilled LEU order in the first half of the year was around $11.7 million, while deliveries to Radiant are not expected to begin until before 2030.
Valuation and the Bull Case
At the current share price, Centrus's equity value is approximately $3.7 billion, based on roughly 20 million Class A and Class B shares outstanding. This valuation is about 7.3 to 8.2 times management's 2026 revenue guidance of $450 million to $500 million. While this is a simplistic comparison, it highlights that the market is already pricing in significant future growth. The company's balance sheet, with $1.87 billion in cash, provides ample room for the planned capital expenditure of $350 million to $500 million this year, primarily for centrifuge manufacturing and industrial buildout.
However, the earnings picture remains uneven. In the second quarter, net income dropped 42% year-over-year to $16.8 million, while advanced-technology costs more than tripled to $10.8 million due to accelerated expansion work at Piketon and Oak Ridge. A major overhang is the company's reliance on government funding. The proposed fiscal 2027 Department of Energy budget did not include additional funds to operate the existing HALEU cascade, and the DOE has not indicated plans to exercise further options. This exposure represented about $0.8 billion of Technical Solutions backlog at the end of June. Commercial prepayments from Radiant and other reactor developers help diversify the funding story, but they do not yet replace that amount.
Radiant's Regulatory Hurdles
Radiant's Kaleidos reactor is a transportable high-temperature gas-cooled design, producing about 3 megawatts of thermal power and roughly 1 megawatt of electricity. The Nuclear Regulatory Commission's project page, updated September 8, shows Radiant in pre-application work for the reactor, with a separate special-nuclear-material license application under review. This regulatory status means that while the fuel order is strategically important, it is financially distant. Radiant must complete testing, licensing, manufacturing, and customer deployment before it can consume HALEU at scale, and each step could alter the volume or timing of fuel that ultimately reaches Centrus's income statement.
What to Watch Next
Investors seeking a stronger bull case should look for disclosures of the Radiant contract's value or a visible increase in customer advances, progress on Piketon's commercial construction milestones, or Radiant's first full-power test clearing remaining authorization steps. A firm federal funding path for continued HALEU operations would also remove a major uncertainty. On the bearish side, the risk is that contract headlines continue to outpace actual capacity, revenue, and margins. Wednesday's price action suggests the market is waiting for numbers. The Radiant deal is useful evidence that reactor developers are willing to help fund U.S. enrichment, but until the economics are disclosed, it is not enough on its own to justify higher earnings estimates.
